Article

Targeting the ERK/MAPK Pathway in Cancer: Oncogenic Mechanisms, Therapeutic Resistance, and Emerging Gene-Based Strategies

2026-08-17

Abstract excerpt

The extracellular signal-regulated kinase 1/2 (ERK1/2) cascade is a central effector of receptor tyrosine kinase-RAS-RAF-MEK signalling and a major therapeutic axis in oncology. Persistent ERK output supports cell-cycle progression, survival, invasion, angiogenesis and tumour-microenvironment remodelling, but pathway dependence is shaped by tumour lineage, driver class, co-mutations and feedback architecture. This...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1c9dcc81-08f8-556c-ba07-262475928a1e
DOI: 10.20944/preprints202608.1093.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeting the ERK/MAPK Pathway in Cancer: Oncogenic Mechanisms, Therapeutic Resistance, and Emerging Gene-Based StrategiesDOI 10.20944/preprints202608.1093.v1Read

BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Semantic proximity Read

Targeting pathological ERK1/2 signaling in cancer and beyondSemantic proximity Read

Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.Semantic proximity Read

The MEK/ERK Network as a Therapeutic Target in Human CancerSemantic proximity Read

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2Semantic proximity Read

Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in KRAS-Mutant CancersSemantic proximity Read

BRAF mutation predicts sensitivity to MEK inhibition.Semantic proximity Read

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2.Semantic proximity Read

Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK.Semantic proximity Read

BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers.Semantic proximity Read

Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in <i>KRAS</i> -Mutant CancersSemantic proximity Read

BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications.Semantic proximity Read